Tags

Type your tag names separated by a space and hit enter

Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study.
Nutrition 2009; 25(2):147-54N

Abstract

OBJECTIVE

Previous studies examining the effect of tea drinking on cardiovascular health have produced mixed results due to their observational nature and qualitatively and quantitatively imprecise definitions of active tea components. The objective of this study was to determine if a standardized and defined decaffeinated green tea (Camellia sinensis) product lowers blood pressure, serum lipids, oxidative stress, and markers of chronic inflammation.

METHODS

A randomized, double-blind, placebo-controlled, parallel study on 111 healthy adult volunteers 21-70 y old was performed. We administered a standardized capsule of Camellia sinensis compounds (CSC) twice a day. Before and after 3 wk, blood pressure, serum lipids, serum amyloid-alpha (a marker of chronic inflammation), and serum malondialdehyde (a marker of oxidative stress) were measured.

RESULTS

After 3 wk, CSC lowered systolic and diastolic blood pressures by 5 and 4 mmHg, respectively. After 3 mo, systolic blood pressure remained significantly lower. CSC lowered serum amyloid-alpha by 42% and lowered malondialdehyde by 11.9%. In men, there were 10- and 9-mg/dL reductions in total and low-density lipoprotein (LDL) cholesterol, respectively. In all subjects with a baseline LDL cholesterol level >99 mg/dL, there was 9 mg/dL lowering of total and LDL cholesterol. Adverse effects were mild and few and not different from placebo.

CONCLUSION

CSC was effective for decreasing, in as quickly as 3 wk, blood pressure, LDL cholesterol, oxidative stress, and a marker of chronic inflammation, all independent cardiovascular risk factors.

Authors+Show Affiliations

Food Science and Human Nutrition Department, University of Florida, Gainesville, FL, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18848434

Citation

Nantz, Meri P., et al. "Standardized Capsule of Camellia Sinensis Lowers Cardiovascular Risk Factors in a Randomized, Double-blind, Placebo-controlled Study." Nutrition (Burbank, Los Angeles County, Calif.), vol. 25, no. 2, 2009, pp. 147-54.
Nantz MP, Rowe CA, Bukowski JF, et al. Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. Nutrition. 2009;25(2):147-54.
Nantz, M. P., Rowe, C. A., Bukowski, J. F., & Percival, S. S. (2009). Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. Nutrition (Burbank, Los Angeles County, Calif.), 25(2), pp. 147-54. doi:10.1016/j.nut.2008.07.018.
Nantz MP, et al. Standardized Capsule of Camellia Sinensis Lowers Cardiovascular Risk Factors in a Randomized, Double-blind, Placebo-controlled Study. Nutrition. 2009;25(2):147-54. PubMed PMID: 18848434.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. AU - Nantz,Meri P, AU - Rowe,Cheryl A, AU - Bukowski,Jack F, AU - Percival,Susan S, Y1 - 2008/10/09/ PY - 2008/03/05/received PY - 2008/07/02/revised PY - 2008/07/18/accepted PY - 2008/10/14/pubmed PY - 2009/4/17/medline PY - 2008/10/14/entrez SP - 147 EP - 54 JF - Nutrition (Burbank, Los Angeles County, Calif.) JO - Nutrition VL - 25 IS - 2 N2 - OBJECTIVE: Previous studies examining the effect of tea drinking on cardiovascular health have produced mixed results due to their observational nature and qualitatively and quantitatively imprecise definitions of active tea components. The objective of this study was to determine if a standardized and defined decaffeinated green tea (Camellia sinensis) product lowers blood pressure, serum lipids, oxidative stress, and markers of chronic inflammation. METHODS: A randomized, double-blind, placebo-controlled, parallel study on 111 healthy adult volunteers 21-70 y old was performed. We administered a standardized capsule of Camellia sinensis compounds (CSC) twice a day. Before and after 3 wk, blood pressure, serum lipids, serum amyloid-alpha (a marker of chronic inflammation), and serum malondialdehyde (a marker of oxidative stress) were measured. RESULTS: After 3 wk, CSC lowered systolic and diastolic blood pressures by 5 and 4 mmHg, respectively. After 3 mo, systolic blood pressure remained significantly lower. CSC lowered serum amyloid-alpha by 42% and lowered malondialdehyde by 11.9%. In men, there were 10- and 9-mg/dL reductions in total and low-density lipoprotein (LDL) cholesterol, respectively. In all subjects with a baseline LDL cholesterol level >99 mg/dL, there was 9 mg/dL lowering of total and LDL cholesterol. Adverse effects were mild and few and not different from placebo. CONCLUSION: CSC was effective for decreasing, in as quickly as 3 wk, blood pressure, LDL cholesterol, oxidative stress, and a marker of chronic inflammation, all independent cardiovascular risk factors. SN - 0899-9007 UR - https://www.unboundmedicine.com/medline/citation/18848434/Standardized_capsule_of_Camellia_sinensis_lowers_cardiovascular_risk_factors_in_a_randomized_double_blind_placebo_controlled_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0899-9007(08)00323-7 DB - PRIME DP - Unbound Medicine ER -